drugset / Trial / NCT06627244

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

NCT06627244

Phase 2 Recruiting 30 enrolled University of Miami Immunocore Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.

Timeline

Start
2025-02-14
Primary completion
2028-02-17
Completion
2031-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Tebentafusp Protein / enzyme biologic 68 ug Intravenous

Indications